Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Femasys Inc., a biomedical company, focuses on women's healthcare market in the United States. The company develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; FemCerv, a biopsy device for endocervical curettage; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. It also commercializes FemVue saline-air device in the United States, Europe, Canada, Japan, and internationally. The company offers its infertility products to obstetrics-gynecological physicians, related healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. In addition, it provides non-surgical product technologies. Femasys Inc. was incorporated in 2004 and is based in Suwanee, Georgia.

Femasys Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

ATLANTA, JUNE 24, 2026 (GLOBE NEWSWIRE) -- FEMASYS INC. (NASDAQ: FEMY), A LEADING BIOMEDICAL INNOVATOR FOCUSED ON MAKING FERTILITY AND NON-SURGICAL PERMANENT BIRTH CONTROL MORE ACCESSIBLE AND COST-EFFECTIVE FOR WOMEN WORLDWIDE, ANNOUNCED TODAY THAT IT RECEIVED FORMAL NOTICE FROM THE NASDAQ STOCK MARKET LLC (NASDAQ) CONFIRMING THE COMPANY HAS REGAINED COMPLIANCE WITH LISTING RULE 5550(A)(2), THE MINIMUM BID PRICE REQUIREMENT FOR CONTINUED LISTING AND THAT THE MATTER IS NOW CLOSED.

FEMASYS REGAINS COMPLIANCE WITH NASDAQ LISTING REQUIREMENTS

-- NEW CATHETER COMPLEMENTS FEMVUE AND SUPPORTS STREAMLINED IN-OFFICE FERTILITY EVALUATION -- -- NEW CATHETER COMPLEMENTS FEMVUE AND SUPPORTS STREAMLINED IN-OFFICE FERTILITY EVALUATION --

FEMASYS EXPANDS FERTILITY CARE PORTFOLIO IN EUROPE WITH CE MARK APPROVAL FOR FEMHSG CATHETER

-- WITH FERTILITY RATES AT HISTORIC LOWS, FEMASYS ADVANCES ACCESS TO EARLY INFERTILITY CARE THROUGH FEMASEED COMPLETE, ENABLING OB/GYNS TO TREAT PATIENTS WITHIN THEIR OWN PRACTICES -- -- WITH FERTILITY RATES AT HISTORIC LOWS, FEMASYS ADVANCES ACCESS TO EARLY INFERTILITY CARE THROUGH FEMASEED COMPLETE, ENABLING OB/GYNS TO TREAT PATIENTS WITHIN THEIR OWN PRACTICES --

FEMASYS ANNOUNCES FINANCIAL RESULTS FOR QUARTER ENDED MARCH 31, 2026 AND PROVIDES CORPORATE UPDATE

-- INTEGRATED SPERM PREPARATION AND INTRATUBAL INSEMINATION DRIVE EARLIER INTERVENTION AND STREAMLINED, IN-OFFICE CARE WITHIN ROUTINE OB/GYN PRACTICE -- ATLANTA, MAY 05, 2026 (GLOBE NEWSWIRE) -- FEMASYS INC. (NASDAQ: FEMY), A LEADING BIOMEDICAL INNOVATOR FOCUSED ON MAKING FERTILITY AND NON-SURGICAL PERMANENT BIRTH CONTROL MORE ACCESSIBLE AND COST-EFFECTIVE FOR WOMEN WORLDWIDE, ANNOUNCED TODAY THE FIRST REVENUE-GENERATING COMMERCIAL USE OF ITS FERTILITY PORTFOLIO IN THE OBGYN SETTING, LED BY FEMASEED AS A FIRST-LINE INFERTILITY TREATMENT. THE PROCEDURE WAS SUPPORTED BY FEMSPERM, ENABLING IN-OFFICE SPERM PREPARATION AND ADVANCING THE SHIFT OF FERTILITY CARE TO WOMEN'S PRIMARY PHYSICIAN, WHERE EARLIER INTERVENTION CAN IMPROVE ACCESS AND OUTCOMES.

FEMASYS ENABLES OB/GYNS TO DELIVER FIRST-LINE FERTILITY TREATMENT WITH INITIAL COMMERCIAL USE OF FEMASEED COMPLETE

-- ENROLLMENT UNDERWAY IN FDA-AUTHORIZED FINALE PIVOTAL TRIAL DEMONSTRATING EXECUTION TOWARD FEMBLOC U.S. APPROVAL -- -- ENROLLMENT UNDERWAY IN FDA-AUTHORIZED FINALE PIVOTAL TRIAL DEMONSTRATING EXECUTION TOWARD FEMBLOC U.S. APPROVAL --

FEMASYS ANNOUNCES FINANCIAL RESULTS FOR YEAR ENDED DECEMBER 31, 2025 AND PROVIDES CORPORATE UPDATE

ATLANTA, FEB. 27, 2026 (GLOBE NEWSWIRE) -- FEMASYS INC. (NASDAQ: FEMY), A LEADING BIOMEDICAL INNOVATOR MAKING FERTILITY AND NON-SURGICAL PERMANENT BIRTH CONTROL MORE ACCESSIBLE AND COST-EFFECTIVE TO WOMEN WORLDWIDE, ANNOUNCED TODAY IT HAS GRANTED TO TWO NEW NON-EXECUTIVE EMPLOYEES WHO BEGAN THEIR EMPLOYMENT WITH FEMASYS IN FEBRUARY 2026 OPTIONS TO PURCHASE 185,000 SHARES OF FEMASYS COMMON STOCK.

FEMASYS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

-- ADVANCES REIMBURSEMENT STRATEGY IN THE U.S. FOR FEMASEED, AN INTENDED FIRST-STEP INFERTILITY TREATMENT -- ATLANTA, FEB. 23, 2026 (GLOBE NEWSWIRE) -- FEMASYS INC. (NASDAQ: FEMY), A LEADING BIOMEDICAL INNOVATOR MAKING FERTILITY AND NON-SURGICAL PERMANENT BIRTH CONTROL MORE ACCESSIBLE AND COST-EFFECTIVE TO WOMEN WORLDWIDE, ANNOUNCED TODAY THAT IT HAS RECEIVED NOTICE FROM THE AMERICAN MEDICAL ASSOCIATION (AMA) CPT EDITORIAL PANEL APPROVING A NEW, UNIQUE CATEGORY III CURRENT PROCEDURAL TERMINOLOGY (CPT) CODE COVERING THE USE OF FEMASEED FOR INTRATUBAL INSEMINATION (ITI), A PROCEDURE THAT DELIVERS SPERM DIRECTLY INTO THE FALLOPIAN TUBE WHERE CONCEPTION OCCURS. THE APPROVED CATEGORY III CPT CODE IS EXPECTED TO BE ISSUED PUBLICLY BY THE AMA WITH AN EFFECTIVE DATE OF JANUARY 1, 2027. APPROVAL OF THIS CATEGORY III CPT CODE REPRESENTS AN IMPORTANT STEP IN ADVANCING THE REIMBURSEMENT STRATEGY FOR FEMASEED TO SUPPORT BROADER CLINICAL ADOPTION, PROVIDER UTILIZATION, AND EXPANDED PATIENT ACCESS TO THIS FIRST-STEP INFERTILITY TREATMENT OPTION.

FEMASYS RECEIVES AMA CPT EDITORIAL PANEL APPROVAL FOR NEW CATEGORY III CPT CODE FOR FEMASEED INTRATUBAL INSEMINATION

PARTNERSHIP ENABLES BROADER ADOPTION OF FEMASEED THROUGH A TRUSTED COMMUNITY HEALTH PROVIDER SERVING A LARGE, ENGAGED PATIENT POPULATION PARTNERSHIP ENABLES BROADER ADOPTION OF FEMASEED THROUGH A TRUSTED COMMUNITY HEALTH PROVIDER SERVING A LARGE, ENGAGED PATIENT POPULATION

FEMASYS ANNOUNCES PARTNERSHIP WITH REFUAH HEALTH CENTER TO EXPAND FIRST-LINE ACCESS TO FEMASEED IN COMMUNITY-BASED CARE

-- INNOVATIVE SINGLE-DEVICE SOLUTION INTEGRATES PROVEN FEMVUE AND FEMCHEC  TECHNOLOGIES TO SUPPORT FALLOPIAN TUBE EVALUATION AND IMPROVE WORKFLOW EFFICIENCY-- ATLANTA, DEC. 18, 2025 (GLOBE NEWSWIRE) -- FEMASYS INC. (NASDAQ: FEMY), A LEADING BIOMEDICAL INNOVATOR MAKING FERTILITY AND NON-SURGICAL PERMANENT BIRTH CONTROL MORE ACCESSIBLE AND COST-EFFECTIVE TO WOMEN WORLDWIDE, ANNOUNCED TODAY IT HAS RECEIVED 510(K) CLEARANCE FROM THE UNITED STATES FOOD AND DRUG ADMINISTRATION (FDA) FOR ITS FEMVUE CONTROLLED DEVICE, AN INNOVATIVE DIAGNOSTIC SOLUTION DESIGNED FOR CONTROLLED CONTRAST DELIVERY TO EVALUATE FALLOPIAN TUBE STATUS. THE NEXT-GENERATION FEMVUE CONTROLLED DEVICE INTEGRATES FEATURES OF THE COMPANY'S ORIGINAL FEMVUE AND FEMCHEC TECHNOLOGIES INTO A SINGLE FDA-CLEARED PRODUCT, ENABLING MULTIPLE CLINICAL USES WHILE STREAMLINING MANUFACTURING AND PRACTICE WORKFLOWS.

FEMASYS SECURES U.S. FDA CLEARANCE FOR NEXT-GENERATION FEMVUE DIAGNOSTIC DEVICE

LAS VEGAS--(BUSINESS WIRE)--PHARMACYTE BIOTECH, INC. (NASDAQ:PMCB) (PHARMACYTE OR THE COMPANY), TODAY ANNOUNCED THE SUCCESSFUL MONETIZATION OF ITS STAKE IN FEMASYS INC. (NASDAQ: FEMY), FURTHER VALIDATING THE COMPANY'S STRATEGIC APPROACH TO CAPITAL DEPLOYMENT AND STRENGTHENING ITS ALREADY SOLID FINANCIAL POSITION. FOLLOWING THE MONETIZATION OF THE STAKE, PHARMACYTE'S CASH AND MARKETABLE SECURITIES ARE EXPECTED TO INCREASE TO APPROXIMATELY $20 MILLION, UP FROM $13.3 MILLION AS OF JULY 31, 202.

Femasys Inc.

FEMY

Price

Financial Reports

No items found.

Press Releases

Femasys Inc.

FEMY.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

FEMY